Liver Disease Clinical Trials in Philadelphia

Showing 61-80 of 91 trials

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

NCT01951209

Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States veterans. Cirrhosis is associated with impaired antibody responses and increased risk of bacterial infections. We have recently identified that cirrhosis is associated with abnormalities of memory B-cells, cells that make antibodies and help protect against bacterial infections. We have identified that chemicals associated with gut bacteria might play a role in causing these B-cell abnormalities. It is well known that gut bacteria have increased access to the blood in individuals with cirrhosis, a process called bacterial translocation. We hypothesize that reducing bacteria counts in the gut by using poorly-absorbed antibiotics (also known as selective gut decontamination) will partially reverse losses of memory B-cells in cirrhosis by reducing bacterial translocation.

Liver CirrhosisChronic Hepatitis C

David E. Kaplan, MD MSc13 participantsStarted Nov 2016

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 4< 1 mile

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934

Retrospective/Prospective, open-label study using sofosbuvir based DAA therapy to treat HIV/HCV coinfected pre or post liver transplant participants

HIVHepatitis CCirrhosis

University of California, San Francisco68 participantsStarted Aug 2016

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States +5 more locations

TERMINATED< 1 mile

Validation of Point of Care Liver Function Tests

NCT03800069

This study is testing the accuracy of a point of care device that tests liver function within 20 minutes. The target population will be any adult who had liver function tests ordered and to be drawn on the same day as enrollment.

Liver DiseasesHealthyCirrhosis, Liver+1 more

University of Pennsylvania68 participantsStarted Dec 2018

Philadelphia, Pennsylvania, United States

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

Validation of Point of Care Liver Function Tests

Liver Disease Trials in Other Cities

Monitoring of Symptoms and Cognitive Function Using Telehealth

The Patient-Reported Outcomes Project of HCV-TARGET

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Adult-to-Adult Living Donor Liver Transplantation Study

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation

Tesamorelin Effects on Liver Fat and Histology in HIV

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Other Conditions in Philadelphia